BrainCool AB (BRAIN) AI Stock Analysis

• Market Cap: €402.39M
• Dividend Yield: N/A
• Average Volume (3M): 156.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 72.05%
• EPS Growth: 33.68%
• Country: SE
• Employees: 20
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 253,391,190
• 10 Day Avg. Volume: 181,870
• 30 Day Avg. Volume: 156,172
• PEG Ratio: -0.92
• Price to Book (P/B): 2.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: ―

BrainCool AB's overall stock score reflects strong revenue growth offset by significant challenges in profitability and cash flow. The technical indicators are mixed, showing stability but not strong momentum. Valuation metrics are unfavorable due to current unprofitability and lack of dividends. These factors contribute to a moderate overall score, indicating potential but also significant risks.

BrainCool AB Business Overview & Revenue Model

Company Description

BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.

How the Company Makes Money

BrainCool AB generates revenue primarily through the sale of its medical cooling systems and related accessories to healthcare facilities, including hospitals and emergency medical services. The company may also engage in strategic partnerships with medical institutions and distributors to expand the market reach of its products. Additionally, BrainCool might receive funding from research grants or collaborations aimed at furthering the development and efficacy of its technologies. The company's earnings are influenced by its ability to innovate, secure regulatory approvals, and expand its market presence internationally.

BrainCool AB Financial Statement Overview

Summary

BrainCool AB demonstrates strong revenue growth but faces challenges in profitability and cash flow generation. The balance sheet reflects a robust equity position, but the lack of profitability and negative cash flows represent risks that need to be addressed to ensure sustainable growth and financial stability.

Income Statement

BrainCool AB shows significant revenue growth from 2019 to 2024, but continues to incur large net losses, with a negative EBIT and EBITDA margin. The revenue growth rate is promising, but the company is struggling with profitability, as indicated by negative gross and net profit margins.

Balance Sheet

The company maintains a strong equity base and no debt, resulting in a favorable debt-to-equity ratio. However, continuous losses are a concern for long-term sustainability. The equity ratio indicates a strong asset base supported by equity, but the company must manage its liabilities effectively to improve financial stability.

Cash Flow

BrainCool AB's cash flow is under pressure with negative free cash flow and operating cash flow over the years, despite stable financing cash flow. The company's reliance on external financing raises concerns about its ability to generate cash organically, which is critical for its long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.09M	39.96M	23.23M	17.59M	9.26M	7.03M
Gross Profit	-15.44M	13.13M	12.12M	-46.16M	-48.93M	-36.74M
EBITDA	-32.35M	-34.06M	-49.86M	-35.07M	-32.16M	-30.39M
Net Income	-40.98M	-44.04M	-61.28M	-45.61M	-38.75M	-37.30M
Balance Sheet
Total Assets	149.43M	162.04M	133.28M	133.67M	99.35M	94.28M
Cash, Cash Equivalents and Short-Term Investments	8.32M	31.40M	25.06M	41.21M	13.58M	12.02M
Total Debt	0.00	0.00	0.00	0.00	35.00M	0.00
Total Liabilities	12.03M	16.11M	21.54M	17.44M	54.12M	33.58M
Stockholders Equity	137.40M	145.93M	111.74M	116.23M	45.23M	60.70M
Cash Flow
Free Cash Flow	-72.01M	-70.20M	-67.23M	-53.67M	-35.06M	-46.82M
Operating Cash Flow	-66.59M	-62.64M	-61.16M	-46.27M	-24.25M	-39.25M
Investing Cash Flow	-7.84M	-7.57M	-6.17M	-7.59M	-10.82M	-8.37M
Financing Cash Flow	76.92M	76.80M	50.93M	81.28M	36.39M	46.57M

BrainCool AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.62, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.62 is Neutral, neither overbought nor oversold. The STOCH value of 51.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BRAIN.

BrainCool AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
BRAIN	50 Neutral	€402.39M	―	-33.54%	―	72.05%	33.68%
6Y1		€38.68M	―	-19.17%	―	―	―
3F8		€36.90M	―	-159.24%	―	―	―
7AC		€32.91M	―	-88.97%	―	―	―
1DO		€49.49M	―	-48.55%	―	―	―
MN2		€33.79M	―	-17.16%	―	―	―